MYEYE Ê IS THE FIRST INTERNATIONAL HUB AIMED AT ACCELERATION OF WORLD PRECLINICAL PROJECTS ON EYE DISEASES. THROUGH INNOVATIVE AND PHYSIOLOGICALLY RELEVANT PLATFORMS IN VITRO AND EX VIVO, HIGHLY INFORMATIVE PRECLINICAL MODELS, AND NEW APPROACHES TO THE PROFILING OF BIOLOGICAL SAMPLES, MYEYE WILL ALLOW TO ACCELERATE THE PRECLINICAL PART OF THE DEVELOPMENT OF DRUGS FOR OCULAR DISEASES UP TO PHASE 1B, COMBINING WITH SPECIFIC FUNCTIONAL TESTS NEW TRANSVERSAL BIOMARKERS FOR THE VARIOUS PHASES, ABLE TO ACCOMPANY THE DEVELOPMENT OF THE MOLECULE UP TO THE INITIAL CLINICAL PHASE (PHASE 1B) WITH QUANTITATIVE AND CONSTANT MARKERS MYEYE REPRESENTS THE FIRST WORLDWIDE EXAMPLE OF INTEGRATION OF THE MOST INNOVATIVE TECHNOLOGICAL PLATFORMS. AIMED AT OPTIMISING THE VARIOUS STAGES OF PRECLINICAL DEVELOPMENT OF NEW DRUGS FOR DISEASES OFÂOCK, ALLOWING A FASTER AND MORE EFFICIENT PROCESSING OF CANDIDATE MOLECULES, BOTH FOR WIDESPREAD DISEASES Q